Physicians' Academy for Cardiovascular Education

PCSK9 and HMGCR genetic variants are associated to risk of type 2 diabetes

PCSK9 and HMGCR genetic variants are associated to risk of type 2 diabetes

Literature - Ference et al., NEJM and Schmidt et al., Lancet Diabetes Endocrinol

Main results

In the study of Ference and colleagues, 7 variants of PCSK9 and 6 variants of HMGCR were included.

Combining 50 studies including 245,942 individuals and data from repositories including another 322,506 individuals, Schmidt and colleagues observed 51,623 cases of incident or prevalent T2DM.

Conclusion

Both studies showed that genetic variants that mimic the effect of PCSK9 inhibitors had effects on lower LDL-c levels and the risk of cardiovascular events and the risk of diabetes. This was similar to variants that mimic the effect of statins when measured per unit change in the LDL-c level. Furthermore, it was shown that both variants together were independent and additive. These data suggest that treatment with a PCSK9 inhibitor, used either alone or in combination with a statin, should reduce the risk of cardiovascular events by approximately 20% per decrease of 1mmol/L in LDL-c but also may increase the risk of new-onset diabetes. However, the corresponding proportional reduction in cardiovascular risk was much greater than the increased risk of diabetes.

References

Show references

Find the article of Ference and colleagues online at NEJM Find the article of Schmidt and colleagues online at Lancet Diabetes Endocrinol

Share this page with your colleagues and friends: